Trial Outcomes & Findings for Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications (NCT NCT00809146)

NCT ID: NCT00809146

Last Updated: 2016-06-17

Results Overview

The primary outcome was termination of seizures before arrival in the emergency department (ED) without the need for the paramedics to provide rescue therapy. Subjects did not reach the primary outcome if they were having seizures on arrival in the emergency department or if they received rescue medication before arrival. Termination of seizures on arrival was determined according to the clinical judgment of the attending emergency physician and was based on examination of the subjects, their clinical course, and results of any routine diagnostic testing.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

1023 participants

Primary outcome timeframe

Duration of prehospital care, outcome is determined upon arrival at the ED on the day of enrollment (average 20 minutes).

Results posted on

2016-06-17

Participant Flow

Subjects treated for status epilepticus in the prehospital setting by paramedics were enrolled at the scene between June 2009 and January 2011. A total of 1023 subject enrollments represented 893 unique subjects with a reenrollment rate of 13%. RAMPART involved 4314 paramedics, 33 EMS agencies, and 79 receiving hospitals across the United States.

Number of patients enrolled includes any repeat enrollments for those who presented to emergency medical services (EMS) with status epilepticus more than once. The number assigned to treatment in the intention-to-treat analysis includes every patient who was enrolled in the study but only the initial enrollment for those enrolled more than once.

Participant milestones

Participant milestones
Measure
Intramuscular (IM) Anticonvulsant
This group gets active treatment with an anticonvulsant by the intramuscular route of administration. IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.
Intravenous (IV) Anticonvulsant
This group gets active treatment with an anticonvulsant by the intravenous route of administration. IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
Overall Study
STARTED
448
445
Overall Study
COMPLETED
448
445
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Intramuscular (IM) Anticonvulsant
n=448 Participants
This group gets active treatment with an anticonvulsant by the intramuscular route of administration. IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.
Intravenous (IV) Anticonvulsant
n=445 Participants
This group gets active treatment with an anticonvulsant by the intravenous route of administration. IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
Total
n=893 Participants
Total of all reporting groups
Age, Continuous
43 years
STANDARD_DEVIATION 22 • n=99 Participants
44 years
STANDARD_DEVIATION 22 • n=107 Participants
43 years
STANDARD_DEVIATION 22 • n=206 Participants
Age, Customized
0-5 years
32 participants
n=99 Participants
29 participants
n=107 Participants
61 participants
n=206 Participants
Age, Customized
6-10 years
15 participants
n=99 Participants
20 participants
n=107 Participants
35 participants
n=206 Participants
Age, Customized
11-20 years
28 participants
n=99 Participants
21 participants
n=107 Participants
49 participants
n=206 Participants
Age, Customized
21-40 years
114 participants
n=99 Participants
112 participants
n=107 Participants
226 participants
n=206 Participants
Age, Customized
41-60 years
169 participants
n=99 Participants
169 participants
n=107 Participants
338 participants
n=206 Participants
Age, Customized
>61 years
90 participants
n=99 Participants
94 participants
n=107 Participants
184 participants
n=206 Participants
Sex: Female, Male
Female
198 Participants
n=99 Participants
207 Participants
n=107 Participants
405 Participants
n=206 Participants
Sex: Female, Male
Male
250 Participants
n=99 Participants
238 Participants
n=107 Participants
488 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
49 Participants
n=99 Participants
57 Participants
n=107 Participants
106 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
310 Participants
n=99 Participants
290 Participants
n=107 Participants
600 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
89 Participants
n=99 Participants
98 Participants
n=107 Participants
187 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
3 Participants
n=99 Participants
5 Participants
n=107 Participants
8 Participants
n=206 Participants
Race (NIH/OMB)
Asian
8 Participants
n=99 Participants
14 Participants
n=107 Participants
22 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
2 Participants
n=99 Participants
1 Participants
n=107 Participants
3 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
229 Participants
n=99 Participants
224 Participants
n=107 Participants
453 Participants
n=206 Participants
Race (NIH/OMB)
White
165 Participants
n=99 Participants
183 Participants
n=107 Participants
348 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
9 Participants
n=99 Participants
5 Participants
n=107 Participants
14 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
32 Participants
n=99 Participants
13 Participants
n=107 Participants
45 Participants
n=206 Participants
Region of Enrollment
United States
448 participants
n=99 Participants
445 participants
n=107 Participants
893 participants
n=206 Participants
Dose tier
children with an estimated weight of 13 to 40 kg
62 participants
n=99 Participants
59 participants
n=107 Participants
121 participants
n=206 Participants
Dose tier
Children estimated >40kg and All Adults
386 participants
n=99 Participants
386 participants
n=107 Participants
772 participants
n=206 Participants
History of epilepsy
Yes
293 participants
n=99 Participants
295 participants
n=107 Participants
588 participants
n=206 Participants
History of epilepsy
No
111 participants
n=99 Participants
103 participants
n=107 Participants
214 participants
n=206 Participants
History of epilepsy
Not documented
44 participants
n=99 Participants
47 participants
n=107 Participants
91 participants
n=206 Participants
Final diagnosis
Status epilepticus
404 participants
n=99 Participants
399 participants
n=107 Participants
803 participants
n=206 Participants
Final diagnosis
Nonepileptic spell
31 participants
n=99 Participants
32 participants
n=107 Participants
63 participants
n=206 Participants
Final diagnosis
Undetermined
13 participants
n=99 Participants
14 participants
n=107 Participants
27 participants
n=206 Participants

PRIMARY outcome

Timeframe: Duration of prehospital care, outcome is determined upon arrival at the ED on the day of enrollment (average 20 minutes).

The primary outcome was termination of seizures before arrival in the emergency department (ED) without the need for the paramedics to provide rescue therapy. Subjects did not reach the primary outcome if they were having seizures on arrival in the emergency department or if they received rescue medication before arrival. Termination of seizures on arrival was determined according to the clinical judgment of the attending emergency physician and was based on examination of the subjects, their clinical course, and results of any routine diagnostic testing.

Outcome measures

Outcome measures
Measure
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
Number of Subjects With Termination of Seizures at ED Arrival With no Rescue Therapy Given
329 participants
282 participants

SECONDARY outcome

Timeframe: anytime before 30 minutes after ED arrival

Endotracheal intubation performed or attempted by EMS or within 30 minutes after ED arrival is abstracted from the ED record physician and nursing records. Endotracheal intubation includes placement of a definitive tracheal airway (oro-, naso-, cricothyroidotomy, or tracheostomy) for support of respirations or protection of airway. Non-definitive and/or non-tracheal airways (oral or nasal airways, laryngeal mask airways, or esophageal obturator airways) are not included if the patient is not subsequently intubated unless specifically deemed to have been used in lieu of tracheal intubation.

Outcome measures

Outcome measures
Measure
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
Number of Subjects With Endotracheal Intubation Within 30 Min After ED Arrival
63 participants
64 participants

SECONDARY outcome

Timeframe: at ED disposition on day of enrollment

Hospital and ICU admission from the ED, and length of stay, is abstracted from the hospital admission record. ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient.

Outcome measures

Outcome measures
Measure
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
Number of Subjects Hospitalized
258 participants
292 participants

SECONDARY outcome

Timeframe: at time of disposition on day of enrollment

Hospital and ICU admission from the ED, and length of stay, is abstracted from the hospital admission record. ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient.

Outcome measures

Outcome measures
Measure
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
Number of Subjects Admitted to an Intensive Care Unit (ICU)
128 participants
161 participants

SECONDARY outcome

Timeframe: within 12 hours after ED arrival

Acute seizure recurrence is defined as any further convulsive or electrographic seizures occurring in the first 12 hours of hospitalization, if they require additional antiepileptic medications, in subjects that had been determined not to be having seizures on ED arrival.

Outcome measures

Outcome measures
Measure
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
Number of Subjects With Recurrent Seizure Within 12 Hours After ED Arrival
51 participants
47 participants

SECONDARY outcome

Timeframe: participants were followed for the duration of hospital stay, an average of 6 days

Acute hypotension is defined as a systolic blood pressure of \< 90 mmHg sustained for greater than 5 minutes and for which the patient was treated with a continuous IV infusion of a vasopressor.

Outcome measures

Outcome measures
Measure
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
Number of Subjects With Hypotension
12 participants
13 participants

SECONDARY outcome

Timeframe: participants were followed for the duration of hospital stay, an average of 6 days

IM injection site complications are defined as any symptoms or signs of injury or reaction at the site of the study IM injection requiring treatment. This includes extensive hematoma requiring treatment (decompression, pressure dressings, or discontinuation of anticoagulant or antithrombotic medications). Treatment does not include imaging without other interventions. This definition also includes wound infection requiring antibiotic therapy, retained foreign bodies requiring exploration and removal, or other similar wound problems.

Outcome measures

Outcome measures
Measure
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
Number of Subjects With IM Injection-site Complications
4 participants
2 participants

SECONDARY outcome

Timeframe: participants were followed for the duration of hospital stay, an average of 6 days

IV insertion site complications are defined as any symptoms or signs of injury or reaction at the site of the study IV placed by paramedics and used for study medication. This includes thrombosis, phlebitis, or skin infection requiring specific treatment including compresses, antibiotics, or wound care.

Outcome measures

Outcome measures
Measure
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
Number of Subjects With IV Injection-site Complications
0 participants
3 participants

SECONDARY outcome

Timeframe: participants were followed for the duration of hospital stay, an average of 6 days

Population: All participants with ICU length of stay data

Continuous days of initial ICU stay from time of admission

Outcome measures

Outcome measures
Measure
IM Midazolam
n=123 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
IV Lorazepam
n=155 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
Length of Intensive Care Unit (ICU) Stay in Days
5.7 days
Standard Deviation 9.5
4.1 days
Standard Deviation 4.7

SECONDARY outcome

Timeframe: participants were followed for the duration of hospital stay, an average of 6 days

Population: All subjects with hospital length of stay data

Continuous acute care inpatient hospital days from day of admission until discharge

Outcome measures

Outcome measures
Measure
IM Midazolam
n=251 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
IV Lorazepam
n=285 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
Length of Hospital Stay in Days
6.7 days
Standard Deviation 10.0
5.5 days
Standard Deviation 6.4

Adverse Events

IM Midazolam

Serious events: 137 serious events
Other events: 103 other events
Deaths: 0 deaths

IV Lorazepam

Serious events: 156 serious events
Other events: 95 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
IM Midazolam
n=514 participants at risk
Subjects in whom the study IM autoinjector contained active treatment with midazolam
IV Lorazepam
n=509 participants at risk
Subjects in whom the study IV infusion contained active treatment with lorazepam
Nervous system disorders
Depressed level of consciousness
9.5%
49/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
8.8%
45/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Respiratory, thoracic and mediastinal disorders
Respiratory depression
6.4%
33/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
10.0%
51/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Nervous system disorders
Convulsion
6.4%
33/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
7.7%
39/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Nervous system disorders
Mental status changes
1.8%
9/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
2.0%
10/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Infections and infestations
Sepsis/SIRS/organ failure
1.6%
8/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
1.6%
8/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Infections and infestations
Pneumonia/ Aspiration pneumonia
0.39%
2/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
2.2%
11/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Cardiac disorders
Myocardial infarction
0.97%
5/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
1.4%
7/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Cardiac disorders
Hypotension
0.97%
5/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
1.4%
7/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
0.97%
5/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.98%
5/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
General disorders
Alcohol/Drug withdrawal syndrome
0.97%
5/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.98%
5/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Nervous system disorders
Cerebral hemorrhage
0.78%
4/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Renal and urinary disorders
Renal failure, acute
0.78%
4/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Nervous system disorders
Ischemic stroke
0.39%
2/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.39%
2/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Cardiac disorders
Atrial fibrillation
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.59%
3/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Endocrine disorders
Hypoglycemia
0.39%
2/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Blood and lymphatic system disorders
Anemia
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Cardiac disorders
Bradycardia
0.39%
2/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Cardiac disorders
Cardiac arrest
0.39%
2/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Vascular disorders
Deep vein thrombosis
0.39%
2/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
General disorders
Hypothermia
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.39%
2/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Respiratory, thoracic and mediastinal disorders
Pulmonary edema
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.39%
2/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
General disorders
Pyrexia
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.39%
2/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Respiratory, thoracic and mediastinal disorders
Apnea
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain mass
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Nervous system disorders
Encephalopathy
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Vascular disorders
Pulmonary embolism
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
General disorders
Chest pain
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Nervous system disorders
Delirium
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
General disorders
Hematoma
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Renal and urinary disorders
Hematuria
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Endocrine disorders
Hyperglycemic hyperosmolar nonketotic syndrome
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Gastrointestinal disorders
Pancreatitis acute
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Respiratory, thoracic and mediastinal disorders
Pneumothorax
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Nervous system disorders
Subarachnoid hemorrhage
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Psychiatric disorders
Suicidal ideation
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Blood and lymphatic system disorders
Transfusion reaction
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Cardiac disorders
Ventricular tachycardia
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Psychiatric disorders
Pseudoseizures
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Cardiac disorders
Cardiogenic shock
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Infections and infestations
Cellulitis
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Musculoskeletal and connective tissue disorders
Fracture
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Cardiac disorders
Hypertension
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Respiratory, thoracic and mediastinal disorders
Hypoxia
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Respiratory, thoracic and mediastinal disorders
Post-extubation stridor/airway obstruction
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Psychiatric disorders
Psychosis
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Respiratory, thoracic and mediastinal disorders
Stridor
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Blood and lymphatic system disorders
Thrombocytopenia
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Skin and subcutaneous tissue disorders
Toxic epidermal necrolysis
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Gastrointestinal disorders
Vomiting/Nausea
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.

Other adverse events

Other adverse events
Measure
IM Midazolam
n=514 participants at risk
Subjects in whom the study IM autoinjector contained active treatment with midazolam
IV Lorazepam
n=509 participants at risk
Subjects in whom the study IV infusion contained active treatment with lorazepam
Nervous system disorders
Convulsion
8.8%
45/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
7.5%
38/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Nervous system disorders
Mental status changes
3.9%
20/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
3.9%
20/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
Gastrointestinal disorders
Vomiting/Nausea
2.9%
15/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
4.5%
23/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
General disorders
Pyrexia
4.5%
23/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
2.8%
14/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.

Additional Information

Robert Silbergleit MD, Principal Investigator

University of Michigan

Phone: 734-232-2142

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place